v2.4.0.6

Reporting Segments (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2011
Segment Reporting [Abstract] |
Reporting Segments | Reportable Segments The structure of the Company’s internal organization is divided into the following three reportable segments, which are also the Company's operating segments: Energy and Chemicals (“E&C”), Distribution and Storage (“D&S”) and BioMedical. The Company’s reportable segments are business units that are each managed separately because they manufacture, offer and distribute distinct products with different production processes and sales and marketing approaches. The E&C segment sells brazed aluminum and air-cooled heat exchangers, cold boxes and liquefied natural gas vacuum-insulated pipe to natural gas, petrochemical processing and industrial gas companies who use them for the liquefaction and separation of natural and industrial gases. The D&S segment sells cryogenic bulk storage systems, cryogenic packaged gas systems, cryogenic systems and components, beverage liquid CO 2 systems, cryogenic flow meter systems and cryogenic services to various companies for the storage and transportation of both industrial and natural gases. The BioMedical segment sells medical respiratory products, biological storage systems and other oxygen products. Due to the nature of the products that each segment sells, there are no intersegment sales. Corporate includes operating expenses for executive management, accounting, tax, treasury, human resources, information technology, legal, internal audit, risk management and stock-based compensation expenses that are not allocated to the reporting segments. The Company evaluates performance and allocates resources based on operating income or loss from continuing operations before net interest expense, financing costs amortization expense, foreign currency gain or loss, income taxes and noncontrolling interest. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note A.
| Year Ended December 31, 2011
| Reportable Segments
| Energy and Chemicals |  | Distribution and Storage |  | BioMedical |  | Corporate |  | Total
Sales from external customers | $ | 205,033 |  |  | $ | 390,332 |  |  | $ | 199,220 |  |  | $ | — |  |  | $ | 794,585 |
Depreciation and amortization expense | 7,417 |  |  | 11,767 |  |  | 7,588 |  |  | 1,143 |  |  | 27,915 |
Operating income (loss) | 27,489 |  |  | 61,415 |  |  | 35,911 |  |  | (34,821 | ) |  | 89,994 |
Total assets(A)(B) | 203,067 |  |  | 556,688 |  |  | 226,729 |  |  | 187,729 |  |  | 1,174,213 |
Capital expenditures | 5,228 |  |  | 7,808 |  |  | 6,692 |  |  | 2,652 |  |  | 22,380 |
| Year Ended December 31, 2010
| Reportable Segments
| Energy and Chemicals |  | Distribution and Storage |  | BioMedical |  | Corporate |  | Total
Sales from external customers | $ | 137,801 |  |  | $ | 269,293 |  |  | $ | 148,361 |  |  | $ | — |  |  | $ | 555,455 |
Depreciation and amortization expense | 7,338 |  |  | 10,474 |  |  | 5,197 |  |  | 568 |  |  | 23,577 |
Operating income (loss) | 6,121 |  |  | 41,934 |  |  | 30,698 |  |  | (31,249 | ) |  | 47,504 |
Total assets(A)(C) | 188,407 |  |  | 513,215 |  |  | 227,138 |  |  | 26,079 |  |  | 954,839 |
Capital expenditures | 973 |  |  | 8,563 |  |  | 4,594 |  |  | 2,809 |  |  | 16,939 |
| Year Ended December 31, 2009
| Reportable Segments
| Energy and Chemicals |  | Distribution and Storage |  | BioMedical |  | Corporate |  | Total
Sales from external customers | $ | 255,074 |  |  | $ | 252,197 |  |  | $ | 90,187 |  |  | $ | — |  |  | $ | 597,458 |
Depreciation and amortization expense | 7,335 |  |  | 10,104 |  |  | 3,591 |  |  | 382 |  |  | 21,412 |
Operating income (loss) | 61,852 |  |  | 39,888 |  |  | 15,912 |  |  | (23,318 | ) |  | 94,334 |
Total assets(A)(D) | 205,482 |  |  | 486,620 |  |  | 135,977 |  |  | 98,424 |  |  | 926,503 |
Capital expenditures | 2,707 |  |  | 7,168 |  |  | 2,022 |  |  | 1,293 |  |  | 13,190 |
_______________
(A) | Corporate assets at December 31, 2011, 2010 and 2009 consist primarily of cash, cash equivalents, short term investments and deferred income taxes.
(B) | Total assets at December 31, 2011 include goodwill of $83,215, $158,381 and $47,174 for the Energy and Chemicals, Distribution and Storage and BioMedical segments, respectively.
(C) | Total assets at December 31, 2010 include goodwill of $83,215, $148,010 and $44,027 for the Energy and Chemicals, Distribution and Storage and BioMedical segments, respectively.
(D) | Total assets at December 31, 2009 include goodwill of $83,215, $144,290 and $37,027 for the Energy and Chemicals, Distribution and Storage and BioMedical segments, respectively.
A reconciliation of the total of the reportable segments’ operating income to consolidated income before income taxes and minority interest is presented below:
| Year Ended December 31,
| 2011 |  | 2010 |  | 2009
Operating income | $ | 89,994 |  |  | $ | 47,504 |  |  | $ | 94,334 |
Other expense (income): |  |  |  |  |
Interest expense, net | 23,371 |  |  | 16,196 |  |  | 15,817 |
Amortization of deferred financing costs | 4,383 |  |  | 3,063 |  |  | 1,616 |
Gain on acquisition of business | — |  |  | (1,124 | ) |  | (6,954 | )
Foreign currency loss (gain) | (734 | ) |  | 871 |  |  | (687 | )
Income before income taxes and minority interest | $ | 62,974 |  |  | $ | 28,498 |  |  | $ | 84,542 |
| Year Ended December 31,
| 2011 |  | 2010 |  | 2009
Product Sales Information: |  |  |  |  |
Energy and Chemicals Segment |  |  |  |  |
Heat exchangers | $ | 158,975 |  |  | $ | 113,313 |  |  | $ | 172,374 |
Cold boxes and LNG VIP | 46,058 |  |  | 24,488 |  |  | 82,700 |
| $ | 205,033 |  |  | $ | 137,801 |  |  | $ | 255,074 |
Distribution and Storage Segment |  |  |  |  |
Cryogenic bulk storage systems | $ | 183,932 |  |  | $ | 117,907 |  |  | $ | 135,523 |
Cryogenic packaged gas systems and beverage liquid CO 2 systems | 147,526 |  |  | 103,129 |  |  | 80,278 |
Cryogenic systems and components | 33,038 |  |  | 20,221 |  |  | 10,987 |
Cryogenic services | 25,836 |  |  | 28,036 |  |  | 25,409 |
| $ | 390,332 |  |  | $ | 269,293 |  |  | $ | 252,197 |
BioMedical Segment |  |  |  |  |
Medical respiratory products | $ | 138,411 |  |  | $ | 95,666 |  |  | $ | 41,793 |
Biological storage systems | 60,809 |  |  | 52,695 |  |  | 43,966 |
Other | — |  |  | — |  |  | 4,428 |
| 199,220 |  |  | 148,361 |  |  | 90,187 |
Total Sales | $ | 794,585 |  |  | $ | 555,455 |  |  | $ | 597,458 |
| Year Ended December 31, 2011 |  | Year Ended December 31, 2010 |  | Year Ended December 31, 2009
Geographic Information: | Sales |  | Long-Lived Assets |  | Sales |  | Long-Lived Assets |  | Sales
United States | $ | 503,011 |  |  | $ | 326,439 |  |  | $ | 391,691 |  |  | $ | 391,428 |  |  | $ | 441,583 |
Czech Republic | 87,285 |  |  | 78,921 |  |  | 72,486 |  |  | 86,680 |  |  | 79,865 |
China | 71,752 |  |  | 73,469 |  |  | 45,203 |  |  | 69,243 |  |  | 28,641 |
Germany | 122,001 |  |  | 95,932 |  |  | — |  |  | — |  |  | — |
Other Non-U.S. Countries | 10,536 |  |  | 2,085 |  |  | 46,075 |  |  | 1,392 |  |  | 47,369 |
Total | $ | 794,585 |  |  | $ | 576,846 |  |  | $ | 555,455 |  |  | $ | 548,743 |  |  | $ | 597,458 |

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration